Form 8-K - Current report:
SEC Accession No. 0000950170-24-125920
Filing Date
2024-11-13
Accepted
2024-11-13 07:00:09
Documents
13
Period of Report
2024-11-13
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K acrv-20241113.htm   iXBRL 8-K 40692
2 EX-99.1 acrv-ex99_1.htm EX-99.1 158094
3 GRAPHIC img28311487_0.jpg GRAPHIC 16059
  Complete submission text file 0000950170-24-125920.txt   351565

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT acrv-20241113.xsd EX-101.SCH 25798
15 EXTRACTED XBRL INSTANCE DOCUMENT acrv-20241113_htm.xml XML 4888
Mailing Address 480 ARSENAL WAY, SUITE 100 WATERTOWN MA 02472
Business Address 480 ARSENAL WAY, SUITE 100 WATERTOWN MA 02472 617-207-8979
Acrivon Therapeutics, Inc. (Filer) CIK: 0001781174 (see all company filings)

EIN.: 825125532 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41551 | Film No.: 241451110
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)